MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Natera Inc

Closed

SectorHealthcare

143.08 2.35

Overview

Share price change

24h

Current

Min

136.95

Max

146.42

Key metrics

By Trading Economics

Income

-22M

-54M

Sales

36M

476M

EPS

-0.41

Profit margin

-11.295

Employees

4,424

EBITDA

-27M

-46M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+40.54% upside

Dividends

By Dow Jones

Next Earnings

8 May 2025

Market Stats

By TradingEconomics

Market Cap

-1.4B

19B

Previous open

140.73

Previous close

143.08

News Sentiment

By Acuity

25%

75%

66 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Natera Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 May 2024, 14:49 UTC

Earnings
Hot Stocks

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

Peer Comparison

Price change

Natera Inc Forecast

Price Target

By TipRanks

40.54% upside

12 Months Forecast

Average 197.67 USD  40.54%

High 251 USD

Low 175 USD

Based on 16 Wall Street analysts offering 12 month price targets forNatera Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

136.56 / 152.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

66 / 386 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.